Fusion Antibodies News

Fusion Antibodies to collaborate with Analytics Engines
Fusion Antibodies plc, experts in antibody engineering and Analytics Engines, an advanced data analytics company, have announced a strategic collaboration to incorporate machine learning (ML) and artificial intelligence (AI) into Fusion Antibodies’ CDRx™ humanization platform.

Humanized antibody Jf5 detects Aspergillus
Towards translational ImmunoPET/MR imaging of invasive Pulmonary Aspergillosis: The Humanized Monoclonal Antibody JF5 detects Aspergillus Lung Infections in Vivo

Fusion Antibodies announces partnership with Protein Alternatives
Fusion Antibodies announces partnership with Protein Alternatives to develop world class humanized antibodies for therapeutic development
Fusion Antibodies plc, a UK-based contract research organisation…











Potential biomarkers for bladder and colon cancer
Non-phosphorylated and Phosphorylated Signal Transduction Peptide (STP) of Tissue Factor (TF) in Urine are Potential Biomarkers for Bladder and Colon Cancer.
Objective
Tissue factor (TF, CD142) is commonly associated with the initiation…











Funding for Queen’s pancreatic cancer drug research in collaboration with Fusion Antibodies
Queen’s University Belfast researchers at the Centre for Cancer Research and Cell Biology (CCRCB) alongside Fusion Antibodies plc have secured a prestigious Medical Research Council (MRC) award to develop a new antibody drug for the treatment of pancreatic cancer.











Fusion Antibodies to double workforce with help from Invest NI
Fusion Antibodies has announced plans to create 28 new jobs. This recruitment drive, supported by Invest NI, will help Fusion Antibodies deliver its services to its growing international customer base.
Invest NI has offered…











Phase 1 of Fusion Antibodies expansion project underway
We are delighted to showcase the progress of Phase 1 of our ambitious expansion project that is now well underway.
As many of you will remember, in December 2017 Fusion Antibodies became one of only three companies in Northern Ireland…











We have made the 2018 NI Dealmakers Awards shortlist!
Fusion Antibodies have been shortlisted for a category at the 2018 Northern Ireland Dealmakers Awards
Fusion Antibodies are absolutely delighted to be shortlisted in the Deal of the Year (£2.5m - £10m) award category in the Insider…











Coming in 2018!
We're delighted to announce that we have some new services launching in 2018!
Developability and Manufacturability Services!
We have developed a range of software analytics delving into the properties of antibodies. These…











Fusion to become third Northern Irish Company listed on the London Stock Exchange
Fusion Antibodies to seek AIM IPO
We are delighted to announce that we are seeking a listing on the AIM Market of the London Stock Exchange and has published its AIM Admission Document which will be available to view here.
We propose…











Fusion Antibodies are attending PEGS Europe
Fusion Antibodies are pleased to be attending PEGS Europe being held on 13-17th November in Lisbon, Portugal.
PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. Last year, in 2016, a record…











Fusion Antibodies are attending BioFIT 2017
Fusion Antibodies are delighted to be attending BioFIT being held on 28-29th November in Strasbourg, France.
BioFIT is the leading partnering event in Europe fortechnology transfer, academia-industry collaborations and early-stage…